The innate immune system has gained significant interest expected to the impressive natural killer (NK) cells ability to surveil and combat pathogens, regardless of major histocompatibility complex. Following the resounding success of CAR-T cell therapy, there has been a burgeoning interest in harnessing the NK therapeutics potential in recent years. Owing to its clinical triumphs, which those achieved by CAR-T cell therapy, this subject has garnered a discernible level of fascination. A captivating realm of investigation within tumor immunotherapy lies in delving into chimeric antigen receptor (CAR) engineering applied to. In the wake of the astounding achievements witnessed with CAR-T cell therapy for CD19 hematologic disorders, CAR-NK cells are emerging as an auspicious adjunctive strategy to cellular therapy following CAR-T cells. It is intriguing that CAR-NK cells exhibit comparable efficacy against malignancies as demonstrated in CAR-T cell therapy, and preliminary clinical investigations have yielded promising outcomes. review aims to furnish a meticulous synopsis of the advancements in CAR-NK cell treatment, encompassing methodologies for generating and genetically manipulating CAR-NK cells. Additionally, it examines the obstacles and future possibilities associated with utilizing CAR-NK as an advanced form of immunotherapy against cancer. The primary aim of this prospective study is clarify reasons behind implementing CAR-NK as a novel approach to anticancer immunotherapy.